TopiVert to present First-In-Human data from its Phase I clinical study with TOP1288 for the treatment of ulcerative colitis at the forthcoming 11th Congress of ECCO in Amsterdam

London, UK, 7 March 2016: TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal tract and eye, announces that it will present Phase I study data results for TOP1288, its lead compound for the treatment of ulcerative colitis (UC), at the 11th Congress of ECCO (European Crohn's and Colitis Organisation) to be held on 16-19 March 2016 in Amsterdam, The Netherlands.

Data from its First-In-Human randomized double-blind placebo-controlled clinical trial of a novel narrow spectrum kinase inhibitor, will be presented on Friday 18 March 2016 in the “Clinical: therapy and observation” session along with a further four TopiVert posters. Senior members of the management and R&D teams will be available at the conference from 17 March to meet with interested parties.

-Ends-

For more information please contact:

TopiVert Pharma Ltd
Steve Webber, Chief Scientific Officer
Nick Staples, Business Development

Consilium Strategic Communications
Mary-Jane Elliott / Ivar Milligan / Hendrik Thys

TopiVert Pharma Ltd
info@topivert.com
+44 (0)20 3763 9468
+44 (0)7818 075816

topivert@consilium-comms.com
+44 (0)20 3709 5700

About TopiVert
TopiVert is a clinical-stage biotechnology company developing narrow spectrum kinase inhibitors as novel, locally-acting medicines for the local treatment of chronic inflammatory diseases of the gastrointestinal tract and eye.

TopiVert’s most advanced drug candidate, TOP1288 for the treatment of ulcerative colitis, has successfully completed Phase I development and a Phase IIa proof of concept study is planned to commence in the middle of this year. The Company also plans to start the clinical development of TOP1630, its candidate for dry eye disease (DED), by early 2017. Current therapies for these debilitating diseases provide inadequate long-term control in a high proportion of patients and considerable unmet medical need remains.
The Company commenced operations in early 2012 and its investors include Imperial Innovations, SV Life Sciences, NeoMed and Johnson & Johnson Innovation – JJDC, Inc..

**About Narrow Spectrum Kinase Inhibitors (NSKIs)**
NSKIs are novel small molecules characterised by broad, potent anti-inflammatory activity together with minimal systemic exposure. Specifically, NSKIs are potent inhibitors of a select range of pivotal kinases involved in inflammatory cascades of both innate and adaptive immunity. Simultaneous targeting of multiple inflammatory components leads to a synergistic activity profile with broad anti-inflammatory effects. The NSKIs are designed to have low bioavailability to reduce their exposure to many of the body’s healthy tissues, enhancing their safety and tolerability profiles in the process. Together, these attributes make NSKIs ideal candidates for treatments in inflammatory diseases where long term therapy demands a sustained effect accompanied by excellent safety and tolerability.

**IBD and Ulcerative Colitis**
Inflammatory Bowel Disease (IBD) is a term used to describe several diseases that involve inflammation of the gastrointestinal tract. The two most common forms of IBD, Crohn’s disease and ulcerative colitis, together affect over 4 million people worldwide. They are both chronic relapsing conditions that cause bloody diarrhoea, abdominal pain and significant reductions in a patient’s quality of life. While their causes are not fully understood, these diseases are characterised by an abnormal inflammatory reaction that leads to damage of the intestinal wall.

Current treatments for ulcerative colitis involve administration of oral, rectal or intravenous/subcutaneous anti-inflammatory and immunomodulatory therapies, including biologics. Despite these products being effective in treating active disease in some patients, their long term use is often hampered by safety and tolerability issues. Furthermore, as many as 40% of patients remain uncontrolled and around 20% require surgery to manage the disease.